Searches for peptides for muscle growth point at a specific compound class in the research literature: growth hormone secretagogues — peptides that prompt the body’s own pituitary to release growth hormone, rather than supplying growth hormone directly. This is a research-grounded account of what the published studies on those compounds actually measured, and, just as importantly, where the evidence is thinner than the marketing around it suggests.
Framing first. Everything below describes laboratory and clinical research. The compounds are supplied by CompoundPlug as research chemicals for laboratory use only, are not authorized by Health Canada for human use, and nothing here is a recommendation, a protocol, or a claim that any compound builds muscle in any person. See Research Use Only.
What “Muscle Growth Peptides” Actually Refers To
The honest starting point is that the phrase covers two mechanistically different things, and conflating them is the single most common error in this topic.
- Growth hormone secretagogues (GHSs) — compounds that raise the body’s own GH and, downstream, IGF-1. This is the class most searches are actually about: CJC-1295, ipamorelin, tesamorelin, sermorelin.
- Tissue-repair peptides — BPC-157, TB-500 — studied for recovery and soft-tissue healing, not for adding muscle mass. They get grouped in because “recovery” and “muscle” sit near each other, but the mechanism is unrelated.
This article is about the first group. The repair peptides are covered separately under Healing Peptides.
The Mechanism: The GH/IGF-1 Axis
Growth hormone is produced in the anterior pituitary and released in pulses, not continuously. Those pulses are governed by two opposing hypothalamic signals: GHRH, which stimulates release, and somatostatin, which suppresses it. Once GH enters circulation, the liver converts much of it into IGF-1, the downstream mediator responsible for most of GH’s tissue-level effects — including muscle protein turnover, lean-mass maintenance, and connective-tissue repair.
The two compound families in this class hit that axis from different angles:
- GHRH analogs — CJC-1295, tesamorelin, sermorelin. These mimic GHRH and bind the GHRH receptor, extending or amplifying the natural GH pulse.
- Ghrelin mimetics / GH secretagogues — ipamorelin. These act on a separate receptor (the ghrelin/GHS receptor) to trigger GH release through an independent pathway.
This is why CJC-1295 and ipamorelin are almost always studied together. They act on two different receptors, so their effects on GH release are additive — the researchers describe the combination as producing a synergistic effect on GH output, hitting the axis from both directions at once.
What the Research Actually Shows — Stated Honestly
This is the part most pages selling these compounds leave out, and it is the most important thing on this page.
The hormonal effect is well established. The muscle-growth outcome is not.
There is a clear distinction between two very different kinds of evidence:
What is solidly demonstrated
That these compounds raise GH and IGF-1 is consistently shown across human trials. A 2006 study in the Journal of Clinical Endocrinology and Metabolism found sustained, dose-dependent increases in GH and IGF-1 in healthy adults over several weeks with CJC-1295. Ipamorelin reliably stimulates GH with a relatively favorable profile — notably, without the cortisol and prolactin elevation seen with older secretagogues. The pharmacology is not in dispute.
What is not solidly demonstrated
Direct evidence that these peptides increase muscle mass in healthy adults is scarce. Most of the human data comes from short-term pharmacokinetic trials measuring hormone levels — not long-term studies measuring muscle. Where body-composition benefits appear, they are largely from GH-deficient populations, older adults, or extrapolation from studies of growth hormone itself rather than the secretagogues. And the changes observed in supervised practice are generally described as modest — lean-mass preservation and body-composition quality rather than dramatic mass gain.
Put plainly: the mechanistic chain (peptide → GH → IGF-1 → muscle protein synthesis) is biologically coherent, and each link individually has support. But the end-to-end claim — that taking these peptides produces meaningful muscle growth in an otherwise healthy trained person — rests more on physiological plausibility and user reports than on direct trial evidence. An honest reading of the literature says the effect on body composition quality is better supported than the effect on muscle volume.
The Compounds Studied in This Class
CJC-1295 (no DAC) + Ipamorelin
The most-studied combination. CJC-1295 (no DAC) is a GHRH analog with a short half-life that supports pulsatile release approximating natural physiology; ipamorelin is a selective ghrelin-receptor agonist. Studied together for GH/IGF-1 elevation, recovery-related signalling, and lean-mass preservation. CompoundPlug supplies the CJC-1295 + Ipamorelin blend.
Tesamorelin
The GHRH analog with the strongest clinical record — it is the only one in this group to have completed full clinical development, studied specifically for visceral fat reduction. Its evidence base is oriented toward body composition and metabolic endpoints rather than muscle hypertrophy. See Tesamorelin.
A note on what raises GH vs. what adds muscle
All of these compounds are, in the end, growth hormone secretagogues. The research question they answer is “does this raise GH?” — and the answer is generally yes. The separate question, “does raised GH from a secretagogue build muscle in a healthy adult?”, is the one the literature has not firmly answered. Keeping those two questions distinct is the whole of an honest read on this topic.
Adverse Effects and Safety Signals
The GH secretagogues are generally reported to have a milder acute adverse-effect profile than many compounds — ipamorelin in particular was designed for selectivity, avoiding the cortisol and prolactin spikes of earlier drugs. Commonly reported effects include injection-site reactions, water retention, transient increases in blood glucose (GH is counter-regulatory to insulin), and headache.
The more substantive caution is mechanistic rather than acute: sustained elevation of GH and IGF-1 is a signalling change with long-term implications that short trials do not capture, and IGF-1 is a growth signal whose chronic elevation is an active area of research interest. This is one reason the compounds are studied under controlled conditions rather than assumed safe for open-ended use.
Regulatory Status in Canada
Tesamorelin is an approved medication in some jurisdictions for a specific indication; the research-grade material supplied here is not that product. CJC-1295 and ipamorelin are not approved as medications for muscle growth or any other consumer indication in Canada.
Research-grade versions carry no DIN, have not been assessed by Health Canada, are not pharmaceutically equivalent to any approved product, and are not substitutes for prescription medicine. CompoundPlug supplies them for laboratory research only.
How CompoundPlug Fits
CompoundPlug supplies the research-grade CJC-1295 + Ipamorelin blend and tesamorelin for laboratory research, each HPLC-tested for purity and mass-spec verified for identity, with the analysis published against the lot number. Because this class is frequently mislabelled and underdosed in the grey market, third-party verification of what is in the vial is the core of how these are supplied. Browse the full class under Growth Peptides, and read the Research Use Only position.
Frequently Asked Questions
What peptides are studied for muscle growth?
The main class is growth hormone secretagogues — compounds that raise the body’s own GH and IGF-1. These include the GHRH analogs CJC-1295, tesamorelin, and sermorelin, and the ghrelin mimetic ipamorelin (usually studied with CJC-1295). BPC-157 and TB-500 are sometimes grouped in but are tissue-repair compounds, not muscle-building ones.
Do growth hormone peptides actually build muscle?
Honestly, the evidence is mixed. That these compounds raise GH and IGF-1 is well established across human trials. That the raised hormone translates into meaningful muscle growth in healthy adults is not — most human data is short-term and measures hormones, not muscle, and body-composition benefits seen in practice are generally modest and better described as lean-mass preservation than dramatic gain. The mechanism is plausible; the end-to-end outcome is under-evidenced.
Why are CJC-1295 and ipamorelin used together?
They act on two different receptors — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin/GH-secretagogue receptor — so their effects on GH release are additive. Researchers describe the combination as producing a synergistic effect on GH output, stimulating the axis from two independent directions at once.
What’s the difference between these and taking growth hormone directly?
Secretagogues stimulate the pituitary to release its own GH in a pulsatile pattern that approximates natural physiology. Exogenous GH supplies the hormone directly and continuously, which carries a different risk profile. Much of the research interest in secretagogues stems from this distinction — the pulsatile pattern is closer to endogenous release.
Are muscle growth peptides legal in Canada?
CJC-1295 and ipamorelin are not approved as medications for muscle growth or any consumer indication in Canada. Tesamorelin is approved in some jurisdictions for a specific medical indication, but research-grade material is not that product. Research-grade versions carry no DIN and are supplied for laboratory research only. Anyone seeking treatment should consult a physician.
This article summarizes published research for informational purposes. It is not medical advice, not a recommendation, and not a claim regarding any research-grade compound. The compounds referenced are supplied for laboratory research use only and are not authorized for human use in Canada.